BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35655198)

  • 1. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer.
    Shibata C; Nakano T; Yasumoto A; Mitamura A; Sawada K; Ogawa H; Miura T; Ise I; Takami K; Yamamoto K; Katayose Y
    BMC Surg; 2022 Jun; 22(1):213. PubMed ID: 35655198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer.
    Ishigami S; Natsugoe S; Hokita S; Che X; Tokuda K; Nakajo A; Iwashige H; Tokushige M; Watanabe T; Takao S; Aikou T
    J Clin Gastroenterol; 2001 Jan; 32(1):41-4. PubMed ID: 11154168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.
    Moriyama J; Oshima Y; Nanami T; Suzuki T; Yajima S; Shiratori F; Funahashi K; Shimada H
    Surg Today; 2021 Oct; 51(10):1638-1648. PubMed ID: 33682011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
    Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
    Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative Serum Carcinoembryonic Antigen Levels Predict Recurrence and Survival of Patients with Pathological T2-4 Gastric Cancer Treated with Curative Gastrectomy.
    Uda H; Kanda M; Tanaka C; Kobayashi D; Inaoka K; Tanaka Y; Hayashi M; Iwata N; Yamada S; Fujii T; Sugimoto H; Murotani K; Fujiwara M; Kodera Y
    Dig Surg; 2018; 35(1):55-63. PubMed ID: 28441659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
    Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
    J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic values of anti-helicobacter pylori antibody combined with serum CA724, CA19-9, and CEA for young patients with early gastric cancer.
    Gong X; Zhang H
    J Clin Lab Anal; 2020 Jul; 34(7):e23268. PubMed ID: 32118318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy.
    Kim DH; Oh SJ; Oh CA; Choi MG; Noh JH; Sohn TS; Bae JM; Kim S
    J Surg Oncol; 2011 Nov; 104(6):585-91. PubMed ID: 21695697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging?
    Lin JX; Wang W; Lin JP; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Zheng CH; Huang CM; Zhou ZW; Li P
    Ann Surg Oncol; 2018 Sep; 25(9):2703-2712. PubMed ID: 29971670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma.
    Qiu MZ; Lin JZ; Wang ZQ; Wang FH; Pan ZZ; Luo HY; Li YH; Zhou ZW; He YJ; Xu RH
    Int J Biol Markers; 2009; 24(4):258-64. PubMed ID: 20082274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer.
    Sawayama H; Iwatsuki M; Kuroda D; Toihata T; Uchihara T; Koga Y; Yagi T; Kiyozumi Y; Eto T; Hiyoshi Y; Ishimoto T; Baba Y; Miyamoto Y; Yoshida N; Baba H
    Surg Today; 2018 Nov; 48(11):994-1003. PubMed ID: 29926189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA19‑9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy.
    Ma X; Zhou X; Guo J; Feng X; Zhao M; Zhang P; Zhang C; Gong S; Wu N; Zhang Y; Zhang X; Ren Z; Zhang P
    BMC Surg; 2024 Jan; 24(1):31. PubMed ID: 38263014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
    Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
    Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of early postoperative tumor marker response in gastric cancer.
    Nam DH; Lee YK; Park JC; Lee H; Shin SK; Lee SK; Lee YC; Cheong JH; Hyung WJ; Noh SH; Kim CB
    Ann Surg Oncol; 2013 Nov; 20(12):3905-11. PubMed ID: 23807661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
    Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
    Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer.
    Li Y; Yang Y; Lu M; Shen L
    Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
    Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
    BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of tumor markers as predictors of prognosis in gastric cancer.
    Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
    Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA19-9 is a significant prognostic marker of patients with stage III gastric cancer.
    Kambara Y; Miyake H; Nagai H; Yoshioka Y; Shibata K; Asai S; Yuasa N
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1918-1924. PubMed ID: 32814681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.